GeneDx Appoints Cunningham to Succeed Stueland

Company GeneDx Event Type CEO transition Modality Not applicable (genomic diagnostics) Asset Exome and genome sequencing platform Target Not applicable Disease Area Rare genetic disease diagnostics Summary GeneDx appointed Everett Cunningham CEO and director effective when he starts, expected by December 15, 2026. Katherine Stueland…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *